Royal Philips (NYSE:PHG) said today new research reports that non-invasive ventilation is a key part of a multi-faceted interventional approach to reduce readmission rates among chronic obstructive pulmonary disease patients.
The study, supported by Philips and published in the Journal of Clinical Sleep Medicine, examined COPD patients hospitalized 2+ times a year who transitioned to patient management programs that included noninvasive positive pressure ventilation, Philips said.
Study results from the 397-patient trial indicated that after switching to patient management programs and receiving NIPPV treatments, readmission rate was reduced by 97% over 12 months, Philips said. Patients in the study received treatment form Philips Respironics Trilogy 100, the company said.
“The results of this are more critical now more than ever, given the industry’s increased focus on the high cost of chronic diseases and the need to reduce the re-hospitalization of COPD patients. The use of Trilogy in this COPD management program is just 1 example of our ability to work with an innovative homecare provider partner to achieve a new kind of COPD care management model that connects and supports the clinician, caregiver, home care provider and the patient at every point along the patient care path,” Philips Respironics vice president Eli Diacopoulos said in prepared remarks.
The cost for COPD patient hospital stays in the U.S. is approximately $29.5 billion, according to Philips, with 30-day readmission rates as high as 22.6%. Readmissions among patients in the trial dropped from 100% in the year before intervention to 2.2% the following year.
“The results of this study indicate that Philips Trilogy with an advanced mode of ventilation AVAPs-AE therapy – in combination with respiratory therapist-led care, medication reconciliation and adequate provision of oxygen therapy – assisted in stabilizing the respiratory condition of patients with COPD. Such better management of the COPD condition allows health systems to not only significantly reduce readmissions and the associated high costs, but also improve the quality of life for some of its most complex patients,” Barnes Healthcare Services director of ventilation management Amy Day said in a press release.
In addition to NIPPV treatment, patients in managed treatment received RT-led respiratory care, medication reconciliation, appropriate oxygen therapy initiation, and patient education, according to the study.
“This study holds promise in how a multi-faceted intervention could assist health systems in significantly improving the care of the patients with advanced stage COPD in their home. The results indicate that patients placed on this advanced mode of non-invasive ventilation, combined with an in-home care program, can reduce hospitalizations and subsequently reduce healthcare utilization. This study is a good foundation to build from and to further validate,” Dr. Sairam Parthasarathy of the University Medical Center Tucson said in a prepared statement.
